German pharmaceutical group STADA has approved an additional €20 million investment in Hemofarm’s production complex, expanding manufacturing capacity at the Serbian pharmaceutical company. The investment will support expanded production at the facility, which forms the core of Hemofarm’s Serbian industrial operations. The company employs around 4,500 people, while medicines manufactured in Serbia are exported to European Union markets, the Middle East and other international destinations.
Germany represents Hemofarm’s largest export market, reflecting the company’s integration into STADA’s wider European production and distribution network.
Expansion of Pharmaceutical Manufacturing Capacity
The new investment will add production capacity at the existing industrial complex. Pharmaceutical manufacturing involves regulatory, technical and quality requirements that include validated production processes, established quality systems and specialised employees. These requirements can make established pharmaceutical production facilities more difficult to relocate than manufacturing operations primarily based on labour costs.
For Serbia, the Hemofarm investment adds to foreign industrial activity with a focus on regulated manufacturing, specialised technical capabilities and exports.
Hemofarm’s Role in Serbia’s Industrial Base
Foreign investment in Serbia has traditionally included automotive components, electrical equipment, metals, machinery and labour-intensive manufacturing. Pharmaceutical production has a different industrial profile, combining regulated manufacturing, specialised engineering and laboratory functions with products that must meet certification and quality requirements for international markets. The latest investment increases the production capacity already established at Hemofarm and further integrates the Serbian facility into STADA’s manufacturing network.
Continued Reinvestment in an Established Facility
Hemofarm represents a model of continued foreign investment in an existing industrial operation rather than a single greenfield manufacturing project. Repeated investment can expand production capacity while maintaining established manufacturing processes, technical expertise and supplier relationships at the facility.
The development also comes as European manufacturers assess supply-chain resilience, production costs and dependence on distant suppliers. Serbia remains outside the European Union while maintaining geographic proximity to EU markets, an established industrial workforce and competitive operating costs. For pharmaceutical manufacturing, these factors are combined with requirements for consistent compliance with European quality and regulatory standards. The continued integration of Hemofarm into STADA’s production system reflects the role of the Serbian facility within the group’s wider manufacturing operations.
